Abstract
Glutathione reductase was purified 34806-fold with a final yield of 85 % from the bovine kidney cortex. Some molecular and kinetic properties of purified enzyme are investigated. Product inhibition studies showed that the enzyme obeys ‘branched’ mechanism: KmNADPH 18 ± 3 μM and KmGSSG 65 ± 5 μM were determined.
Keywords: Glutathione reductase, purification, kinetics, branched mechanism
Protein & Peptide Letters
Title: Purification and Kinetics of Bovine Kidney Cortex Glutathione Reductase
Volume: 17 Issue: 5
Author(s): Berivan Tandogan and N. Nuray Ulusu
Affiliation:
Keywords: Glutathione reductase, purification, kinetics, branched mechanism
Abstract: Glutathione reductase was purified 34806-fold with a final yield of 85 % from the bovine kidney cortex. Some molecular and kinetic properties of purified enzyme are investigated. Product inhibition studies showed that the enzyme obeys ‘branched’ mechanism: KmNADPH 18 ± 3 μM and KmGSSG 65 ± 5 μM were determined.
Export Options
About this article
Cite this article as:
Tandogan Berivan and Ulusu N. Nuray, Purification and Kinetics of Bovine Kidney Cortex Glutathione Reductase, Protein & Peptide Letters 2010; 17 (5) . https://dx.doi.org/10.2174/092986610791112684
DOI https://dx.doi.org/10.2174/092986610791112684 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Oral Anticoagulants in the Management of Polycythemia Vera and Essential Thrombocythemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Nitric Oxide and Arginine Dysregulation: A Novel Pathway to Pulmonary Hypertension in Hemolytic Disorders
Current Molecular Medicine Separation of Bioactive Peptides by Membrane Processes: Technologies and Devices
Recent Patents on Biotechnology Screening of Enzyme Inhibitors from Traditional Chinese Medicine
Combinatorial Chemistry & High Throughput Screening Benefits of SGLT2 Inhibitors Beyond Glycemic Control – A Focus on Metabolic, Cardiovascular and Renal Outcomes
Current Diabetes Reviews Pathophysiology of Type 2 Diabetes in Children and Adolescents
Current Diabetes Reviews Crosstalk between Oxidative and Nitrosative Stress and Arterial Stiffness
Current Vascular Pharmacology NF-κB as a Therapeutic Target for Transcription Factor Decoy Strategy in Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Adverse Events of Proton Pump Inhibitors: Potential Mechanisms
Current Drug Metabolism Fetal Undernutrition and the Programming of Blood Pressure
Current Nutrition & Food Science New Insight Into A1 Adenosine Receptors in Diabetes Treatment
Current Pharmaceutical Design Quality Based Design Approach for Improving Oral Bioavailability of Valsartan Loaded Smedds And Study of Impact of Lipolysis on the Drug Diffusion
Drug Delivery Letters Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) The Role of Hypoxia in Endometrial Cancer
Current Pharmaceutical Biotechnology NO-NSAIDs: From Inflammatory Mediators to Clinical Readouts
Inflammation & Allergy - Drug Targets (Discontinued) Biodiversity as a Source of Bioactive Compounds Against Snakebites
Current Medicinal Chemistry Effect of Mandibular Repositioning Appliances on Inspiratory and Expiratory Total Air
Applied Clinical Research, Clinical Trials and Regulatory Affairs Ruta Montana Evokes Antihypertensive Activity Through an Increase of Prostaglandins Release in L-NAME-Induced Hypertensive Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets The Need for Diagnostic Criteria in Systemic Vasculitis
Current Immunology Reviews (Discontinued) PREFACE
Cardiovascular & Hematological Disorders-Drug Targets